Biocon's Q3 revenue dips; banks on obesity drugs for future growth

Jan 30, 2025 · Revenue from Biocon's biosimilars business, its largest, fell 7.9% to 22.9 billion rupees. ... Biocon's Q3 revenue dips; banks on obesity drugs for future growth. Reuters . Thu, …

CouponFollow Extension

9%
OFF

Biocon's Q3 Revenue Dips; Banks On Obesity Drugs For Future Growth

2 weeks from now

Jan 30, 2025 · Revenue from Biocon's biosimilars business, its largest, fell 7.9% to 22.9 billion rupees. ... Biocon's Q3 revenue dips; banks on obesity drugs for future growth. Reuters . Thu, …

yahoo.com

4%
OFF

Biocon’s Q3 Revenue Dips; Banks On Obesity Drugs For Future Growth

2 weeks from now

Jan 30, 2025 · Revenue from the generics unit fell 2.4%, while revenue from its research services business rose 11%. Biocon, which expects a recovery in its generics business in the next few …

theprint.in

7%
OFF

Biocon Q3FY25 Revenue At Rs 3,856 Cr, Up 7%# EBITDA At Rs 787 …

2 weeks from now

Jan 30, 2025 · Financial Commentary: Q3FY25. Consolidated Total Revenue for Q3FY25 was at Rs 3,856 crore.Reported 7% YoY growth on a like-for-like basis, after adjusting for Branded …

biocon.com

5%
OFF

Biocon Quarterly Results, Biocon Financial Statement & Accounts

2 weeks from now

Biocon's Q3 revenue dips; banks on obesity drugs for future growth. 21.01.2025. ... Biocon Q3 PAT may dip 1.5% YoY to Rs. 199.7 cr: ICICI Direct ... Aurobindo Q3 profit seen up 14%, …

moneycontrol.com

96%
OFF

Biocon's Profit Struggles Continue In Q3; Net Profit Plunges 96%

2 weeks from now

Jan 31, 2025 · Biocon Q3 Profit Plunge: On a year-on-year basis, the company’s total revenue has contracted by 15 per cent to ₹3,856 crore from ₹4,519 crore. ... During the quarter, …

indiatimes.com

9%
OFF

Biocon's Q3 Revenue Dips; Banks On Obesity Drugs For Future Growth

2 weeks from now

Jan 30, 2025 · Revenue from Biocon's biosimilars business, its largest, fell 7.9% to 22.9 billion rupees. Biosimilars are copies of high-priced drugs used to treat illnesses such as rheumatoid …

tradingview.com

3%
OFF

Biocon's Q3 Revenue Dips; Banks On Obesity Drugs For Future Growth

2 weeks from now

Jan 29, 2025 · Indian biopharma company Biocon reported third-quarter revenue on Thursday that fell about 3% when compared with the year-earlier period, which included revenue from its …

marketscreener.com

3%
OFF

Biocon's Q3 Revenue Dips; Banks On Obesity Drugs For Future Growth

2 weeks from now

HYDERABAD (Reuters) - Indian biopharma company Biocon reported third-quarter revenue on Thursday that fell about 3% when compared with the year-earlier per Biocon's Q3 revenue …

newsbreak.com

$100
OFF

Weight-loss Medicines: Biocon Eyes A $100 Billion Jackpot With …

2 weeks from now

Apr 8, 2024 · Weight-loss drugs: Biocon Ltd. is shifting focus to anti-obesity therapies as patents for key medications expire, leading to a surge in generic supply. The Bengaluru-based …

indiatimes.com

9%
OFF

Biocon’s Q3 Revenue Dips; Banks On Obesity Drugs For Future Growth

2 weeks from now

Jan 30, 2025 · Revenue from Biocon’s biosimilars business, its largest, fell 7.9% to 22.9 billion rupees. Biosimilars are copies of high-priced drugs used to treat illnesses such as rheumatoid …

srnnews.com

10%
OFF

Biocon Yearly Results, Biocon Financial Statement & Accounts

2 weeks from now

Biocon's Q3 revenue up 10%; banks on obesity drugs for future growth 31.01.2025 Biocon Consolidated December 2024 Net Sales at Rs 3,821.40 crore, down 3.35% Y-o-Y

moneycontrol.com

9%
OFF

Biocon's Q3 Revenue Dips; Banks On Obesity Drugs For Future Growth

2 weeks from now

Jan 30, 2025 · Revenue from Biocon's biosimilars business, its largest, fell 7.9% to Rs 2,290 crore. Biosimilars are copies of high-priced drugs used to treat illnesses such as rheumatoid …

moneycontrol.com

9%
OFF

Biocon's Q3 Revenue Dips; Banks On Obesity Drugs For Future …

2 weeks from now

Revenue from Biocon's biosimilars business, its largest, fell 7.9% to 22.9 billion rupees. Biosimilars are copies of high-priced drugs used to treat illnesses such as rheumatoid arthritis …

msn.com

FAQs about Biocon's Q3 revenue dips; banks on obesity drugs for future growth Coupon?

How did Biocon perform in 3rd quarter?

Indian biopharma company Biocon reported third-quarter revenue on Thursday that fell about 3% when compared with the year-earlier period, which included revenue from its domestic branded formulation business that has since been divested. Revenue from Biocon's biosimilars business, its largest, fell 7.9% to 22.9 billion rupees. ...

How did Biocon biologics perform in q3fy24?

Biocon Biologics reported revenue from operations of Rs 2,289 crore, reflecting a 14 per cent yearly increase on a like-for-like basis. This growth accounts for adjustments to Q3FY24 revenue, excluding contributions from branded formulations India (BFI) and income from the partial divestment of the BFI business. ...

What was Biocon's net profit in q3fy25?

Bengaluru-based biopharma firm Biocon on Thursday reported a consolidated net profit of Rs 25.1 crore in the third quarter of the financial year 2024-25 (Q3FY25). During the same period in the previous financial year, the company reported a loss of Rs 16 crore. ...

Why did Biocon raise funds?

We reported a strong EBITDA growth of 35% to Rs 723 crore, representing a healthy EBITDA margin of 24%. Core EBITDA grew 49% to Rs 1,069 crore. As a part of our strategy to reduce the acquisition debt, Biocon has raised funds through a partial divestment of its stake in Syngene. ...

How did Biocon biologics perform?

“Biocon Biologics recorded its highest ever quarterly revenue of Rs 1,507 crore, reflecting a growth of 54% on the back of our acquisition of Viatris’ biosimilars business and continued growth in BBL led markets. This strong performance has translated to an EBITDA growth of 53% to Rs 361 crore. ...

Why did Biocon grow 10 per cent sequential revenue?

Siddharth Mittal, chief executive officer and managing director, Biocon, noted, “The 10 per cent sequential revenue growth in the generics business was primarily driven by API sales, supported by an improved performance from generic formulations. We expect to see an improved performance in the quarters ahead.” ...